Beijing Biostar Pharms Co Ltd

Beijing Biostar Pharmaceuticals Co., Ltd. is a synthetic biology-driven biopharmaceutical company focused on the development, manufacturing, and commercialization of oncology products in the People's Republic of China. Its Utidelone injection is being developed for indications including metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis. Utidelone capsules are in development for metastatic breast cancer, triple-negative breast cancer adjuvant intensive, first-line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma. The company is also developing a Utidelone antibody drug conjugate and the BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Incorporated in 2002, it is headquartered in Beijing, China.